Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
QTRX Stock Summary
In the News
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024.
Quanterix to Present at Cowen's 44th Annual Health Care Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen's 44th Annual Health Care Conference. Quanterix's session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast, the general public. In addition to the session, Quanterix will also host one-on-one me.
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results. The call will begin at 8:30 AM Eastern Time. It will be hosted by Masoud Toloue, the Company's President and Chief Executive Officer, and Vandana Sriram, the Company's Chief Financial Offi.
Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 54.88% Upside in Quanterix Corporation (QTRX): Can the Stock Really Move This High?
The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 54.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Quanterix Corporation (QTRX) Q3 2023 Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Ed Joyce - VP, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Jake Allen - Goldman Sachs Dan Brennan - Cowen Puneet Souda - Leerink Partners Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q3 2023 Earnings Call.
7 Stocks to Buy if You Anticipate a Hot November
While enough evidence exists that justify a pessimistic view of the market – in particular, high inflation and high borrowing costs – it's also possible that a hot November could rejuvenate previously embattled stocks to buy. And that's not an entirely speculative proposition.
QTRX Financial details
QTRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.02 | 3.02 | 3.07 | 2.84 | 3.22 | |
Net income per share | -1.45 | -1.1 | -1.6 | -2.61 | -0.86 | |
Operating cash flow per share | -0.93 | -0.82 | -1.33 | -1.3 | -0.5 | |
Free cash flow per share | -1.32 | -0.95 | -1.71 | -1.62 | -0.6 | |
Cash per share | 3.88 | 6.35 | 11.01 | 9.16 | 8.55 | |
Book value per share | 4.58 | 7.21 | 12.25 | 9.7 | 9.23 | |
Tangible book value per share | 3.73 | 6.36 | 11.69 | 9.5 | 9.07 | |
Share holders equity per share | 4.58 | 7.21 | 12.25 | 9.7 | 9.23 | |
Interest debt per share | 0.25 | 1.07 | 0.6 | 1.33 | 1.52 | |
Market cap | 664.29M | 1.33B | 1.53B | 512.32M | 1.03B | |
Enterprise value | 562.8M | 1.18B | 1.15B | 217.69M | 894.86M | |
P/E ratio | -16.28 | -42.18 | -26.46 | -5.3 | -31.79 | |
Price to sales ratio | 11.71 | 15.4 | 13.81 | 4.88 | 8.48 | |
POCF ratio | -25.37 | -56.92 | -31.86 | -10.61 | -54.38 | |
PFCF ratio | -17.94 | -48.72 | -24.81 | -8.54 | -45.3 | |
P/B Ratio | 5.16 | 6.45 | 3.46 | 1.43 | 2.96 | |
PTB ratio | 5.16 | 6.45 | 3.46 | 1.43 | 2.96 | |
EV to sales | 9.92 | 13.65 | 10.42 | 2.07 | 7.39 | |
Enterprise value over EBITDA | -13.53 | -37.33 | -19.66 | -5.06 | -23.4 | |
EV to operating cash flow | -21.49 | -50.46 | -24.04 | -4.51 | -47.34 | |
EV to free cash flow | -15.2 | -43.2 | -18.72 | -3.63 | -39.44 | |
Earnings yield | -0.06 | -0.02 | -0.04 | -0.19 | -0.03 | |
Free cash flow yield | -0.06 | -0.02 | -0.04 | -0.12 | -0.02 | |
Debt to equity | 0.06 | 0.15 | 0.05 | 0.12 | 0.12 | |
Debt to assets | 0.05 | 0.11 | 0.04 | 0.1 | 0.1 | |
Net debt to EBITDA | 2.44 | 4.77 | 6.39 | 6.85 | 3.48 | |
Current ratio | 6.69 | 5.52 | 12.14 | 12.32 | 9.84 | |
Interest coverage | 66.35 | 115.69 | 145.37 | -14.1 | -3.14 | |
Income quality | 0.64 | 0.74 | 0.83 | 0.5 | 0.58 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.92 | 0.69 | 0.84 | 0.01 | 0.78 | |
Research and developement to revenue | 0.29 | 0.23 | 0.25 | 0.25 | 0.21 | |
Intangibles to total assets | 0.14 | 0.09 | 0.04 | 0.02 | 0.01 | |
Capex to operating cash flow | 0.41 | 0.17 | 0.28 | 0.24 | 0.2 | |
Capex to revenue | -0.19 | -0.05 | -0.12 | -0.11 | -0.03 | |
Capex to depreciation | -3.6 | -0.91 | -2.81 | -2.19 | -0.45 | |
Stock based compensation to revenue | 0.11 | 0.12 | 0.14 | 0.15 | 0.14 | |
Graham number | 12.22 | 13.37 | 21.02 | 23.89 | 13.36 | |
ROIC | -0.3 | -0.12 | -0.12 | -0.16 | -0.12 | |
Return on tangible assets | -0.28 | -0.13 | -0.12 | -0.23 | -0.08 | |
Graham Net | 2.89 | 4.79 | 10.13 | 7.74 | 7.27 | |
Working capital | 112.83M | 179.8M | 411.98M | 350.45M | 339.94M | |
Tangible asset value | 105M | 181.95M | 420.79M | 351.42M | 340.89M | |
Net current asset value | 91.37M | 154.69M | 388.38M | 306.14M | 300.31M | |
Invested capital | 0.06 | 0.15 | 0.05 | 0.12 | 0.12 | |
Average receivables | 8.85M | 14.05M | 20.49M | 21.4M | 22.22M | |
Average payables | 5.44M | 6.29M | 8M | 6.52M | 4.44M | |
Average inventory | 8.21M | 12.66M | 18.52M | 19.49M | 19.58M | |
Days sales outstanding | 70.16 | 72.61 | 78.53 | 66.14 | 76.57 | |
Days payables outstanding | 70.53 | 64.97 | 68.84 | 23.85 | 35.62 | |
Days of inventory on hand | 127.73 | 141.97 | 165.88 | 104.35 | 157.83 | |
Receivables turnover | 5.2 | 5.03 | 4.65 | 5.52 | 4.77 | |
Payables turnover | 5.18 | 5.62 | 5.3 | 15.31 | 10.25 | |
Inventory turnover | 2.86 | 2.57 | 2.2 | 3.5 | 2.31 | |
ROE | -0.32 | -0.15 | -0.13 | -0.27 | -0.09 | |
Capex per share | -0.39 | -0.14 | -0.38 | -0.32 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.69 | 0.76 | 0.82 | 0.82 | 0.83 | |
Net income per share | -0.5 | -0.16 | -0.16 | -0.21 | -0.33 | |
Operating cash flow per share | -0.11 | -0.25 | 0.02 | -0.11 | -0.16 | |
Free cash flow per share | -0.15 | -0.26 | 0 | -0.13 | -0.22 | |
Cash per share | 9.12 | 8.82 | 8.79 | 8.7 | 8.48 | |
Book value per share | 9.66 | 9.57 | 9.48 | 9.38 | 9.16 | |
Tangible book value per share | 9.46 | 9.38 | 9.3 | 9.22 | 9 | |
Share holders equity per share | 9.66 | 9.57 | 9.48 | 9.38 | 9.16 | |
Interest debt per share | 1.26 | 1.28 | 1.16 | 1.13 | 1.42 | |
Market cap | 514.67M | 420.67M | 845.49M | 1.02B | 1.04B | |
Enterprise value | 220.04M | 135.6M | 559.33M | 863.15M | 902.95M | |
P/E ratio | -6.92 | -17.23 | -34.86 | -32.93 | -20.87 | |
Price to sales ratio | 20.1 | 14.9 | 27.39 | 33.14 | 32.84 | |
POCF ratio | -125.84 | -44.27 | 1.34K | -252.41 | -173.11 | |
PFCF ratio | -90.53 | -43.65 | -56.37K | -211.29 | -126.33 | |
P/B Ratio | 1.43 | 1.18 | 2.38 | 2.89 | 2.99 | |
PTB ratio | 1.43 | 1.18 | 2.38 | 2.89 | 2.99 | |
EV to sales | 8.59 | 4.8 | 18.12 | 27.99 | 28.62 | |
Enterprise value over EBITDA | -55.8 | -14.29 | -58.5 | -67.28 | -73.46 | |
EV to operating cash flow | -53.8 | -14.27 | 883.62 | -213.18 | -150.89 | |
EV to free cash flow | -38.7 | -14.07 | -37.29K | -178.45 | -110.12 | |
Earnings yield | -0.04 | -0.01 | -0.01 | -0.01 | -0.01 | |
Free cash flow yield | -0.01 | -0.02 | 0 | 0 | -0.01 | |
Debt to equity | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
Debt to assets | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
Net debt to EBITDA | 74.72 | 30.05 | 29.93 | 12.38 | 10.82 | |
Current ratio | 12.32 | 13.96 | 11.87 | 10.84 | 9.84 | |
Interest coverage | -4.6 | -2.74 | 0 | 0 | -1.46 | |
Income quality | 0.22 | 1.56 | -0.1 | 0.52 | 0.48 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.03 | 0.03 | 0.74 | 0.79 | 0.8 | |
Research and developement to revenue | 0.22 | 0.17 | 0.19 | 0.23 | 0.22 | |
Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | |
Capex to operating cash flow | 0.39 | 0.01 | -1.02 | 0.19 | 0.37 | |
Capex to revenue | -0.06 | 0 | -0.02 | -0.03 | -0.07 | |
Capex to depreciation | -1.37 | -0.09 | -0.27 | -0.84 | -0.38 | |
Stock based compensation to revenue | 0.14 | 0.14 | 0.14 | 0.14 | 0.14 | |
Graham number | 10.43 | 5.93 | 5.87 | 6.6 | 8.21 | |
ROIC | -0.03 | -0.02 | -0.02 | -0.03 | -0.04 | |
Return on tangible assets | -0.04 | -0.01 | -0.01 | -0.02 | -0.03 | |
Graham Net | 7.7 | 7.63 | 7.55 | 7.44 | 7.22 | |
Working capital | 350.45M | 349.04M | 347.11M | 345.86M | 339.94M | |
Tangible asset value | 351.42M | 350.2M | 348.88M | 347.35M | 340.89M | |
Net current asset value | 306.14M | 305.99M | 305.2M | 305.32M | 300.31M | |
Invested capital | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
Average receivables | 18.67M | 20.78M | 23.48M | 24.25M | 24.75M | |
Average payables | 2.97M | 3.21M | 2.91M | 4.01M | 4.92M | |
Average inventory | 17.51M | 16.93M | 17.61M | 19.05M | 21.16M | |
Days sales outstanding | 66.83 | 71.87 | 71.2 | 70.29 | 72.5 | |
Days payables outstanding | 26.09 | 20.18 | 24.51 | 31.79 | 24.61 | |
Days of inventory on hand | 114.17 | 133.24 | 137.42 | 132.47 | 109.03 | |
Receivables turnover | 1.35 | 1.25 | 1.26 | 1.28 | 1.24 | |
Payables turnover | 3.45 | 4.46 | 3.67 | 2.83 | 3.66 | |
Inventory turnover | 0.79 | 0.68 | 0.65 | 0.68 | 0.83 | |
ROE | -0.05 | -0.02 | -0.02 | -0.02 | -0.04 | |
Capex per share | -0.04 | 0 | -0.02 | -0.02 | -0.06 |
QTRX Frequently Asked Questions
What is Quanterix Corporation stock symbol ?
Quanterix Corporation is a US stock , located in Billerica of Ma and trading under the symbol QTRX
Is Quanterix Corporation buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $13. The lowest prediction is $13 and the highest is $13
What is QTRX stock prediction ?
What is Quanterix Corporation stock quote today ?
Quanterix Corporation stock price is $23.56 today.
Is Quanterix Corporation stock public?
Yes, Quanterix Corporation is a publicly traded company.